Abstract
Background
Prolongation of the QTc interval may lead to life threatening arrhythmias. QTc prolongation is common in intensive care unit (ICU) patients. The objectives of this study were to identify the role of drug-drug interactions (DDIs) and other predictors (age, sex, cardiovascular diseases, and electrolyte abnormalities) in life threatening QTc prolongation in patients admitted to medical (M), surgical (S) and emergency (E) ICUs.
Methods
This prospective, observational study included patients above the age of 18 years who were admitted to SICU, EICU, and MICU at a tertiary respiratory referral center. Electrocardiogram (ECG) monitoring was performed during the first 5 days of ICU admission. Risk factors and DDIs which were anticipated to be associated with the prolongation of the QTc interval were assessed for all patients.
Results
Two hundred patients were included in the study. QTc prolongation occurred in 10.7% of patients and the majority of patients presenting with QTc prolongation had creatinine levels above 1.3 mg/dL during their 5 days of ICU admission. Incidence of pharmacodynamic (PD) DDIs was significantly higher in patients with QTc prolongation vs. other patients. Creatinine levels above 1.3 mg/dL and PD DDIs were associated with QTc prolongation during 5 days of ICU admission.
Conclusions
High serum creatinine and PD DDIs can increase the risk of QTc prolongation in patients admitted to the ICU. QTc interval measurements should be performed prior to initiation or after starting any drug that is associated with QT prolongation, specifically in patients with the known risk factors.
Author contributions: All the authors have accepted responsibility for the entire content of this manuscript and approved submission.
Conflicts of interest: There is no conflicting interest to be declared by the authors.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
[1] Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007;153:891–9.10.1016/j.ahj.2007.01.040Search in Google Scholar PubMed
[2] Annane D, Sébille V, Duboc D, Le Heuzey JY, Sadoul N, Bouvier E, et al. Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med 2008;178:20–5.10.1164/rccm.200701-031OCSearch in Google Scholar PubMed
[3] Corponi F, Fabbri C, Boriani G, Diemberger I, Albani D, Forloni G, et al. Corrected QT interval prolongation in psychopharmacological treatment and its modulation by genetic variation. Neuropsychobiology 2019;77:67–72.10.1159/000493400Search in Google Scholar PubMed
[4] Smithburger PL, Seybert AL, Armahizer MJ, Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. Expert Opin Drug Saf 2010;9:699–712.10.1517/14740331003739188Search in Google Scholar PubMed
[5] Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881–908.10.1592/phco.23.7.881.32730Search in Google Scholar PubMed
[6] Arunachalam K, Lakshmanan S, Maan A, Kumar N, Dominic P. Impact of drug induced long QT syndrome: a systematic review. J Clin Med Res 2018;10:384–90.10.14740/jocmr3338wSearch in Google Scholar PubMed PubMed Central
[7] Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J 2016;149:139–52.10.1177/1715163516641136Search in Google Scholar PubMed PubMed Central
[8] Tisdale JE, Wroblewski HA, Overholser BR, Kingery JR, Trujillo TN, Kovacs RJ. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT-interval prolonging drugs. Drug Saf 2012;35:459–70.10.2165/11598160-000000000-00000Search in Google Scholar PubMed
[9] Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) study. Crit Care Med 2012;40:394–9.10.1097/CCM.0b013e318232db4aSearch in Google Scholar PubMed
[10] Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247–346.10.1161/CIRCULATIONAHA.106.178233Search in Google Scholar PubMed
[11] Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010;55:934–47.10.1161/CIRCULATIONAHA.109.192704Search in Google Scholar PubMed PubMed Central
[12] Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013–22.10.1056/NEJMra032426Search in Google Scholar PubMed
[13] Ng TM, Olsen KM, McCartan MA, Puumala SE, Speidel KM, Miller MA, et al. Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors. J Pharm Pract 2010;23:19–24.10.1177/0897190009356549Search in Google Scholar PubMed
[14] Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz JH, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf 2006;15:361–8.10.1002/pds.1155Search in Google Scholar PubMed
[15] Khan Q, Ismail M, Haider I. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units. Postgrad Med 2018;130:660–5.10.1080/00325481.2018.1516106Search in Google Scholar PubMed
[16] Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 2016;67:1639–50.10.1016/j.jacc.2015.12.063Search in Google Scholar PubMed
[17] US Department of Health and Human Services. Common Terminology Criteria for adverse Events (CTCaE). Version 4.0, 2009. Available from: http://www.hrc.govt.nz/sites/default/files/CTCaE%20manual%20-%20DMCC.pdf. Accessed: 12 October 2018.Search in Google Scholar
[18] Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002;54:188–202.10.1046/j.1365-2125.2002.01627.xSearch in Google Scholar PubMed PubMed Central
[19] Fernandes FM, Silva EP, Martins RR, Oliveira AG. QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. PloS One 2018;13:e0199028.10.1371/journal.pone.0199028Search in Google Scholar PubMed PubMed Central
[20] Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G. Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol 2017;12:210–22.10.2174/1574884713666180223123947Search in Google Scholar PubMed
[21] Kopp BJ, Erstad BL, Allen ME, Theodorou AA, Priestley G. Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med 2006;34:415–5.10.1097/01.CCM.0000198106.54306.D7Search in Google Scholar
[22] Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care 2013;28:243–9.10.1016/j.jcrc.2012.10.014Search in Google Scholar PubMed
[23] Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687–710.10.1097/FTD.0b013e31815c16f5Search in Google Scholar PubMed
[24] Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharmacol Ther 1998;23:403–16.10.1046/j.1365-2710.1998.00086.xSearch in Google Scholar PubMed
[25] Di Iorio B, Bellasi A. QT interval in CKD and haemodialysis patients. Clin Kidney J 2013;6:137–43.10.1093/ckj/sfs183Search in Google Scholar PubMed PubMed Central
[26] Stewart GA, Gansevoort RO, Mark PB, Rooney E, Mcdonagh TA, Dargie HJ, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005;67:217–26.10.1111/j.1523-1755.2005.00072.xSearch in Google Scholar PubMed
[27] Hage FG, De Mattos AM, Khamash H, Mehta S, Warnock D, Iskandrian AE. QT prolongation is an independent predictor of mortality in end-stage renal disease. Clin Cardiol 2010;33:361–6.10.1002/clc.20768Search in Google Scholar PubMed PubMed Central
© 2019 Walter de Gruyter GmbH, Berlin/Boston
